NASDAQ · QTTB
Q32 Bio Inc.
$8.66-$0.21 (-2.37%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.26% below the high.
Loading market information…
NASDAQ · APDN · USD
Stock price, earnings
Quote as of Oct 6, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Applied DNA Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.24% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Applied DNA Sciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Applied DNA Sciences, Inc. specializes in devising and marketing sophisticated DNA-centric technological solutions across diverse sectors. Its activities encompass nucleic acid-based in vitro diagnostics and the preclinical development and production of nucleic acid-based pharmaceuticals. Furthermore, the company offers robust solutions for bolstering supply chain security, combating counterfeiting, and preventing theft. Key offerings for product authenticity and supply chain integrity include SigNature molecular tags, which imbue products with forensic traceability and protection, thereby strengthening brand defense and supply chain resilience while aiding in criminal identification and prosecution. To facilitate real-time, field-based verification of these tags, they provide SigNify IF portable DNA readers along with corresponding SigNify consumable reagent test kits. The CertainT platform represents a holistic approach, integrating tagging, testing, and tracking capabilities, empowering manufacturers, brands, and trade organizations to substantiate their product claims with verifiable evidence. Within the diagnostic realm, the company produces the LineaTM COVID-19 Assay Kit, a PCR-based molecular diagnostic test. It also offers the safeCircle COVID-19 diagnostic kit, specifically designed to help curtail viral transmission within communal settings such as schools or workplaces. Additionally, Applied DNA Sciences delivers contract research and manufacturing services for the burgeoning nucleic acid-based therapeutic markets during their preclinical phases. This extends to providing contract research for clients involved in preclinical studies of RNA-based drugs and biologics. The company is also at the forefront of developing an innovative technology for the capture and identification of invasive circulating tumor cells, utilizing a proprietary functional assay to isolate live invasive tumor cells and their associated lymphocytes. Operating internationally, the firm maintains a significant footprint across the United States, Europe, and Asia. Founded in 1983, the organization was initially known as Datalink Systems, Inc., before officially changing its name to Applied DNA Sciences, Inc. in 2002. Its corporate headquarters are located in Stony Brook, New York.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:59 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $891.16K+14.84% vs estimate |
| Q4 2023 | Dec 7, 2023 | -$38.98+1.94% vs estimate | $779.74K-53.6% vs estimate |
|---|
| Q3 2023 | Aug 10, 2023 | -$35.980.0% vs estimate | $2.92M+14.07% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.66-$0.21 (-2.37%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.26% below the high.
$0.00$0.00 (0.0%)
RVL Pharmaceuticals plc’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
$0.04-$0.01 (-13.39%)
Aravive, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.37% below the high.
$1.80-$1.37 (-43.22%)
MedAvail Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.39% below the high.
$0.09-$0.03 (-24.84%)
Novan, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.17% below the high.
$6.60-$0.16 (-2.38%)
SeqLL Inc.: Healthcare · Medical - Diagnostics & Research.
$0.08-$0.02 (-15.9%)
Aspira Women's Health Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.74% below the high.
€0.03-€0.00 (-8.38%)
Biophytis S.A.’s quoted price sits in the lower half of its reported 52-week range, 80.88% below the high.
